title: [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
abstract: The investigation involved 50 patients (fludarabin+cyclophosphamide+prednisolone (FCP)--30; fludarabin+mitoxanthrone+prednisolone (FMP)--17; fludarabin+cyclophosphamide--3). FMP proved the most effective (60%). Yet, FCP results were clinically significant (29%). The efficacy of all the procedures was determined by morphological pattern and was reported in low- and intermediategrade non-Hodgkin's disease alone. Insignificant differences in partial remission duration and stabilization were observed between FMP and FCP, e.g. FMP's effect lasted 1 month longer. No complete remissions were reported; tolerance was reasonable. Tentative findings point to the marked efficacy of fludarabin, particularly, in combination with mitoxanthrone, cyclophosphamide and prednisolone for relapse or refractory low- and intermediate-grade non-Hodgkin's disease.
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: V V
authors.initials: VV
authors.lastname: Tikhonova
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine